Company / SG&A Expense
FENNEC PHARMACEUTICALS INC. SG&A Expense History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$23.1M
FY2025
5-year range
$5.4M / $23.1M
FY2021-FY2025
Trend
+12.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 7 consecutive years, from $2M in FY2016 to $23M in FY2025.
Based on SEC 10-K filings.
$23M in FY2025 with a 10-year CAGR of +24.8%.
Increased from $18M to $23M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +24.8%
Key checks
Key Insights
- FENNEC PHARMACEUTICALS INC.'s sg&a expense has grown for 7 consecutive years.
- In FY2025, sg&a expense increased 12.0% year-over-year.
- Lowest sg&a expense in the period was in FY2014.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.1M | +12.0% |
| FY2024 | $20.6M | +16.2% |
| FY2023 | $17.7M | +36.8% |
| FY2021 | $12.9M | +139.8% |
| FY2019 | $5.4M | +7.7% |
| FY2018 | $5.0M | +109.0% |
| FY2017 | $2.4M | +46.8% |
| FY2016 | $1.6M | -35.2% |
| FY2015 | $2.5M | +88.9% |
| FY2014 | $1.3M | -13.7% |
As of FY2025 · SEC 10-K Annual Filings · Updated Jun 24, 2026